- Mutational profiling of newly diagnosed glioblastoma to identify predictive biomarkers of efficacy and safety of anlotinib combination therapy.Lai, Shuzhen; Li, Peijing; Liu, Xiaohui; Liu, Guihong; Xie, Tieming; Zhang, Xing; Wang, Xiaoxuan; Huang, Jing; Tang, Yiqiang; Liu, Zhigang; Shen, Guoping; Li, Chaoming; Lu, Fangxiao; Wang, Lei; Jiang, Fagui; Sun, Caixing; Chen, Yuan Yuan YuanAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent GlioblastomaXu, Qingsheng; Huang, Kaiyuan; Meng, Xiangqi; Weng, Yuxiang; Zhang, Luyuan; Bu, Linghao; Zheng, Xiujue; Cai, Jinquan*; Zhan, Renya*; Chen, Qun*Clinical Cancer Research, 2023, 29(19): 3859-3866.
- Recurrent Oligodendroglioma: Treatment with BevacizumabMarc C., ChamberlainTumors of the Central Nervous System, Volume 8, Springer Netherlands, 255-265, 2012.
会议论文
A phase II study of anlotinib combined with temozolomide in the treatment of patients with recurrent glioblastoma.
3阅读
